Abraham Lee,
Chancellor’s Professor, Biomedical Engineering & Director, Center for Advanced Design & Manufacturing of Integrated Microfluidics,
University of California-Irvine
Abraham (Abe) P. Lee is Professor of Biomedical Engineering (BME) and Mechanical and Aerospace Engineering (MAE) at the University of California, Irvine (UCI). He is Director of the NSF I/UCRC “Center for Advanced Design & Manufacturing of Integrated Microfluidics” (CADMIM). Dr. Lee served as Editor-in-Chief for the Lab on a Chip journal from 2017 to 2020. Prior to UCI, he was at the National Cancer Institute and was a program manager in the Microsystems Technology Office at DARPA (1999-2001), Senior Technology Advisor at National Cancer Institute (NCI) and a group leader with Lawrence Livermore National Lab (LLNL). Over the years, Dr. Lee has pioneered research in applying microfluidics to biomedical applications, and currently focuses on integrated microfluidic systems for precision medicine including liquid biopsy, microphysiological systems, cell engineering, and immunotherapy. His research has contributed to the founding of several start-up companies. He owns 60 issued US patents and is author of over 130 journals articles. Professor Lee was awarded the 2009 Pioneers of Miniaturization Prize and is an elected fellow of the National Academy of Inventors (NAI), the American Institute of Medical and Biological Engineering (AIMBE), the Royal Society of Chemistry (RSC), the American Society of Mechanical Engineering (ASME), the International Academy of Medical and Biological Engineering, and the Biomedical Engineering Society (BMES).
|
|
Chip-Scale Microfluidic Physiological Circulation SystemsTuesday, 27 September 2016 at 17:55 There has been a recent surge in the development of microphysiological systems and organ-on-a-chip for drug screening and regenerative medicine. Over the years, drug screening has mostly been carried out on 2D monolayers in well plates and the drugs are not delivered through blood vessels as in vivo treatments. Through the advancement of microfluidics technologies, we have enabled the automation of biological fluids delivery through physiological vasculature networks that mimic the physiological circulation of the human body. The critical bottleneck is to engineer the microenvironment for the formation of vascularized 3D tissues and to also pump and perfuse the tissue vascular network for on-chip microcirculation. This in vitro model system can be used to screen cancer drugs by mimicking the delivery of the drugs through capillary blood vessels. On the other hand, microfluidics play an important role in the recent advances in liquid biopsy and the ability to specifically isolate and capture rare cells such as circulating tumor cells. These two technologies may go hand-in-hand to connect in vitro screening to in vivo screening with great potential in the development of personalized medicine.
|
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
